Minami Yasunori, Minami Tomohiro, Takita Masahiro, Hagiwara Satoru, Ida Hiroshi, Ueshima Kazuomi, Nishida Naoshi, Kudo Masatoshi
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Hepatol Res. 2020 Jan;50(1):67-74. doi: 10.1111/hepr.13407. Epub 2019 Aug 9.
To retrospectively investigate the potential benefit of ultrasound-ultrasound (US-US) overlay fusion guidance for local controllability of radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC).
Patients (n = 101) with 121 HCCs (mean ± SD, 1.8 ± 0.7 cm) who underwent RFA guided by US-US overlay fusion were included in the retrospective study. By overlaying pre/postoperative US, the tumor image could be projected onto the ablative hyperechoic zone. The ablative margin could thereby be evaluated three-dimensionally during the RFA procedure. As a control group, all 325 patients with 453 HCCs who underwent conventional RFA during the same study period were selected.
The total number of RF needle insertions per tumor for ablation was significantly more in the US overlay fusion group (mean 1.9 vs. 1.2; P < 0.01). The technical success rates of ablation after a single session were 100% (101/101) and 96.6% (314/325) for the US overlay fusion group and the control group, respectively. For early assessment of RFA response, 5-mm safety margins were achieved in 89.3% (108/121) and 47.0% (213/453) of nodules in the US overlay fusion group and the control group, respectively (P < 0.01). During the follow-up period (median 19 months), the 2-year local tumor progression rates were 0.8% (1/121) and 6.0% (27/453) in the US overlay fusion group and the control group, respectively (P = 0.022, log-rank test).
US-US overlay fusion guidance can be highly effective for safety margin achievement in RFA for HCC, providing a lower risk of local tumor progression.
回顾性研究超声-超声(US-US)叠加融合引导在肝细胞癌(HCC)射频消融(RFA)治疗中对局部可控性的潜在益处。
本回顾性研究纳入了101例患者,共121个HCC(平均±标准差,1.8±0.7 cm),这些患者接受了US-US叠加融合引导下的RFA治疗。通过叠加术前/术后超声,可将肿瘤图像投射到消融高回声区。从而在RFA过程中对消融边缘进行三维评估。作为对照组,选取了在同一研究期间接受传统RFA治疗的325例患者,共453个HCC。
US叠加融合组每个肿瘤用于消融的射频针插入总数显著更多(平均1.9次对1.2次;P<0.01)。US叠加融合组和对照组单次消融后的技术成功率分别为100%(101/101)和96.6%(314/325)。对于RFA反应的早期评估,US叠加融合组和对照组分别有89.3%(108/121)和47.0%(213/453)的结节实现了5 mm的安全边缘(P<0.01)。在随访期(中位19个月),US叠加融合组和对照组的2年局部肿瘤进展率分别为0.8%(1/121)和6.0%(27/453)(P = 0.022,对数秩检验)。
US-US叠加融合引导对于HCC的RFA实现安全边缘非常有效,可降低局部肿瘤进展风险。